SCHEMBL12373476

SCHEMBL12373476

CCn1c(C(C)NS(=O)(=O)c2ccc(Cl)c3nonc23)cnc1Oc1ccc(C)cc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 3/20 0.35
MCHR1 Q99705 2/20 0.35
S1PR1 P21453 5/20 0.34
S1PR3 Q99500 1/20 0.34
CNR1 P21554 2/20 0.33
RORA P35398 1/20 0.33
RORC P51449 1/20 0.33
NR1H2 P55055 1/20 0.33
ALDH1A1 P00352 2/20 0.31
NLRP3 Q96P20 1/20 0.31
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
P2RX3 P56373 3/20 0.31
PFKFB3 Q16875 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373541 0.87 ALDH1A1 (0.38) NPBWR1MCHR1S1PR1S1PR3CNR1
SCHEMBL12373533 0.86 KMT2A (0.39) NPBWR1MCHR1S1PR1S1PR3ALDH1A1
SCHEMBL12373720 0.86 ALDH1A1 (0.45) ALDH1A1MEN1MAPTHTTKMT2A
SCHEMBL12373581 0.84 S1PR1 (0.41) S1PR1S1PR3
SCHEMBL12373486 0.84 S1PR1 (0.41) S1PR1S1PR3ALDH1A1MEN1LMNA
SCHEMBL12373514 0.84 PGR (0.39) NPBWR1MCHR1S1PR1S1PR3CNR1
SCHEMBL12373547 0.84 PGR (0.40) NPBWR1MCHR1S1PR1S1PR3ALDH1A1
SCHEMBL12373684 0.82 S1PR1 (0.36) NPBWR1MCHR1S1PR1S1PR3CNR1
SCHEMBL12373589 0.82 S1PR1 (0.40) S1PR1S1PR3CNR1ALDH1A1MAPT
SCHEMBL12373484 0.82 NR3C1 (0.38) NPBWR1MCHR1S1PR1S1PR3CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-7994204-B2 Binding inhibitor of sphingosine-1-phosphate TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-08-09 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182144-A1 BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE S1PR1, S1PR3, S1PR2 NPBWR1 67/4885MCHR1 130/4885S1PR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.